Literature DB >> 2896076

Long-term effects of xamoterol on left ventricular diastolic function and late remodeling: a study in patients with anterior myocardial infarction and single-vessel disease.

H Pouleur1, C van Eyll, C Hanet, P Cheron, A A Charlier, M F Rousseau.   

Abstract

The purpose of the study was to examine whether the prolonged administration of the beta 1-adrenoceptor partial agonist xamoterol could improve left ventricular diastolic function and affect the global remodeling process of the left ventricle after anterior myocardial infarction. In 22 patients with anterior myocardial infarction and single-vessel disease, left ventricular angiography (+ Millar) was performed under basal conditions 1 to 2 months after the acute myocardial infarction. Eight patients were then treated for 3 months with placebo and 14 were treated with xamoterol (200 mg bid) and a second left ventricular angiographic study was performed. Angiograms were digitized frame by frame to derive the diastolic pressure-volume relationship and to compute wall stress. An index of elastic myocardial stiffness was computed at a constant stress of 30 kdynes/cm2 before and after treatment. To evaluate changes in left ventricular shape, segmental areas in anterior and inferior segments were computed and compared at end-diastole and end-systole. After xamoterol, left ventricular end-diastolic pressure and mean diastolic wall stress decreased (from 24 +/- 5 to 15 +/- 5 mm Hg and from 57 +/- 32 to 38 +/- 22 kdynes/cm2, respectively; both p less than .01 vs baseline and vs placebo). These changes were accompanied by a downward shift in the diastolic pressure-volume relationship and by a decrease in the index of myocardial stiffness from 526 +/- 270 to 371 +/- 194 kdynes/cm2 (p less than .02).(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2896076     DOI: 10.1161/01.cir.77.5.1081

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  10 in total

Review 1.  Therapeutic implications of diastolic dysfunction in heart failure.

Authors:  J W Dean; P A Poole-Wilson
Journal:  Postgrad Med J       Date:  1990-11       Impact factor: 2.401

Review 2.  Newer beta blockers and the treatment of hypertension.

Authors:  D McAreavey; R Vermeulen; J I Robertson
Journal:  Cardiovasc Drugs Ther       Date:  1991-06       Impact factor: 3.727

Review 3.  Xamoterol. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use.

Authors:  R Furlong; R N Brogden
Journal:  Drugs       Date:  1988-10       Impact factor: 9.546

Review 4.  Clinical pharmacology and therapeutics.

Authors:  M J Kendall; R C Horton
Journal:  Postgrad Med J       Date:  1990-03       Impact factor: 2.401

Review 5.  Xamoterol, a beta 1-adrenoceptor partial agonist: review of the clinical efficacy in heart failure.

Authors:  H F Marlow
Journal:  Br J Clin Pharmacol       Date:  1989       Impact factor: 4.335

Review 6.  Focus on diastolic dysfunction: a new approach to heart failure therapy.

Authors:  H Pouleur; C Hanet; O Gurné; M F Rousseau
Journal:  Br J Clin Pharmacol       Date:  1989       Impact factor: 4.335

7.  Effects of long-term xamoterol therapy on the left ventricular mechanical efficiency in patients with ischemic heart disease.

Authors:  H Pouleur; C van Eyll; J Etienne; H van Mechelen; A Vuylsteke; M F Rousseau
Journal:  Basic Res Cardiol       Date:  1989       Impact factor: 17.165

Review 8.  Reassessment of digoxin and other low-dose positive inotropes in the treatment of chronic heart failure.

Authors:  J Tauke; D Han; M Gheorghiade
Journal:  Cardiovasc Drugs Ther       Date:  1994-10       Impact factor: 3.727

9.  Predominant beta-adrenoceptor blocking effect of xamoterol averaged over the day in patients with mild to moderate heart failure: insight into the mechanism of its long-term clinical efficacy.

Authors:  H Ozaki; H Sato; M Hori; T Matsuyama; K Imai; H Yokoyama; A Kitabatake; M Inoue; T Kamada
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

10.  Beta-blockers for suspected or diagnosed acute myocardial infarction.

Authors:  Sanam Safi; Naqash J Sethi; Emil Eik Nielsen; Joshua Feinberg; Janus C Jakobsen; Christian Gluud
Journal:  Cochrane Database Syst Rev       Date:  2019-12-17
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.